Julia Scanlon

Nov 9, 2024 | clinicalleader.com | Dan Schell |Jessica Cordes |Matthew Jones |Julia Scanlon

OCTOBER'S BEST FEATURED EDITORIALGovernment Contract Advances Walgreens In Clinical SpaceWalgreen’s new $25 million deal with BARDA (Biomedical Advanced Research and Development Authority) is a huge win for the pharmacy chain. John Campbell, head of DCTs at Walgreens, explains the ins and outs of the study and what could be next for the company regarding its clinical trials division.

May 1, 2024 | clinicalleader.com | Matthew Jones |Julia Scanlon

By Matthew Jones and Julia Scanlon In today’s complex world of clinical trials, the significance of creating favorable site experiences and nurturing strong relationships between sponsors and sites cannot be emphasized enough. As sponsors endeavor to enlist sites and position themselves as the preferred sponsor for projects, it becomes crucial to tackle two fundamental questions: How can we effectively meet the needs of the sites? And how can the sites best support our trial requirements?